The ultimate goal of this project is to develop a Positron Emission Tomography (PET) radiotracer for brain imaging of the cyclic nucleotide phosphodiesterase 10A (PDE10A). PDE10A is specifically expressed in the brain with high levels in striatal medium-sized spiny projection neurons (MSN) where it plays a critical role in the regulation of both cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). Abnormal striatal levels of PDE10A affect striatal output and may contribute substantially to the pathophysiology of schizophrenia, Huntington's disease (HD) and other mental disorders. Decreased striatal PDE10A level has been correlated with the severity of HD, while inhibition of PDE10A has been proposed as a novel therapeutic strategy for treating schizophrenia and related conditions. Thus, a PET radiotracer for PDE10A would be a valuable tool for clinical neuroscience research. To achieve the goal of this project, we first radiolabeled a representative PDE10A compound, 2-((4-(1-[11C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3- yl)phenoxy)-methyl)quinoline ([11C]MP-10) with C-11. MP-10 is a high potency PDE10A inhibitor (IC50 = 0.37 nM) with high selectivity (1000 fold) for PDE10A vs. other PDEs and CNS receptors. We also successfully modified the structure of MP-10 to make a fluorine analogue, TuJF103 (IC50 = 0.27 nM). Preliminary biodistribution evaluation of [11C]MP-10 and [18F]TUJF103 in rats, and microPET imaging studies of both radiotracers in monkeys displayed good contrast between the target (striatal) and the reference (cerebellum) region. However, analysis of the time-activity curves of striatum and cerebellum and subsequent metabolite analysis of rat brain and blood indicated the presence of lipophilic radiolabeled metabolites that accumulate non-specifically in the brain. Such metabolites could limit the clinical utility of either [11C]MP-10 or [18F]TUJF103 as novel PET tracers for imaging PDE10A. To overcome such concerns, this proposal will optimize the structure of MP-10 to synthesize new analogues with high affinity and selectivity for PDE10A;radiolabel lead candidates with C-11 or F-18 and then use in vivo methods to validate optimal PET radiotracers for imaging PDE10A in the brain. Consequently, the specific aims of the R21 component include: (1) synthesize new analogues by structural optimization of MP-10;(2) measure the affinities of new analogues in vitro;(3) radiolabel the ligands having high affinities (IC50<15 nM) and high selectivity (>100 fold) with C-11 or F-18;(4) conduct biodistribution and brain uptake studies of radiotracers in rats to identify at least two promising candidates.
The specific aims of the R33 component will be the continued evaluation of these candidate radiotracers in primates with the goal of identifying a PET tracer suitable for translational clinical evaluation for imaging PDE10A in the brain with PET.
Huntington's disease is a progressive neurological disorder of motor, cognitive, and psychiatric disturbances. It was reported more than 15,000 Americans have HD. At least other 150,000 have a 50% risk of developing the disease and thousands more of their relatives live with the possibility that they might develop HD. A PET radiotracer of PDE10A may help physician to quantify the progression of Huntington Disease based on the PET measurement of PDE10A level in patients with the Huntington disease patients.
|Liu, Hui; Jin, Hongjun; Yue, Xuyi et al. (2017) PET Study of Sphingosine-1-Phosphate Receptor 1 Expression in Response to Vascular Inflammation in a Rat Model of Carotid Injury. Mol Imaging 16:1536012116689770|
|Yue, Xuyi; Jin, Hongjun; Liu, Hui et al. (2017) Synthesis, resolution, and in vitro evaluation of three vesicular acetylcholine transporter ligands and evaluation of the lead fluorine-18 radioligand in a nonhuman primate. Org Biomol Chem 15:5197-5209|
|Han, Junbin; Liu, Hui; Liu, Chunling et al. (2017) Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response. Nucl Med Commun 38:372-382|
|Yue, Xuyi; Jin, Hongjun; Luo, Zonghua et al. (2017) Chiral resolution of serial potent and selective ?1 ligands and biological evaluation of (-)-[18F]TZ3108 in rodent and the nonhuman primate brain. Bioorg Med Chem 25:1533-1542|
|Rosenberg, Adam J; Liu, Hui; Jin, Hongjun et al. (2016) Design, Synthesis, and In Vitro and In Vivo Evaluation of an (18)F-Labeled Sphingosine 1-Phosphate Receptor 1 (S1P1) PET Tracer. J Med Chem 59:6201-20|
|Liu, Hui; Jin, Hongjun; Yue, Xuyi et al. (2016) PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis. Mol Imaging Biol 18:724-32|
|Jin, Hongjun; Zhang, Xiang; Yue, Xuyi et al. (2016) Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates. Nucl Med Biol 43:131-9|
|Liu, Hui; Jin, Hongjun; Yue, Xuyi et al. (2016) Comparison of [(11)C]TZ1964B and [(18)F]MNI659 for PET imaging brain PDE10A in nonhuman primates. Pharmacol Res Perspect 4:e00253|
|Yue, Xuyi; Bognar, Christopher; Zhang, Xiang et al. (2016) Automated production of [¹?F]VAT suitable for clinical PET study of vesicular acetylcholine transporter. Appl Radiat Isot 107:40-46|
|Yue, Xuyi; Jin, Hongjun; Liu, Hui et al. (2015) A potent and selective C-11 labeled PET tracer for imaging sphingosine-1-phosphate receptor 2 in the CNS demonstrates sexually dimorphic expression. Org Biomol Chem 13:7928-39|
Showing the most recent 10 out of 34 publications